Thalidomide-piperazine-Boc is a derivative of thalidomide, which is a medication that was originally used to treat morning sickness in pregnant women, but was later found to cause serious birth defects. Thalidomide-piperazine-Boc is being researched as a potential treatment for various conditions, including cancer and autoimmune diseases.
Chemical name: N-(2-(7-(1,3-dioxoisoindolin-2-yl) piperazin-1-yl)ethyl)-4-(N-boc-amino)phthalimide Molecular formula: C25H28N4O6 Formula weight: 472.52 g/mol CAS No: 2222114-64-7
Top ten keywords from Google and Synonyms:
Health benefits of this product: Research into the health benefits of Thalidomide-piperazine-Boc is ongoing, but preliminary studies suggest it may have potential as a treatment for various conditions. It has been shown to have anti-inflammatory and immunomodulatory effects, and may also inhibit angiogenesis (the formation of new blood vessels), which is important for tumor growth. It may be effective in treating multiple myeloma, leukemia, and other cancers, as well as autoimmune diseases such as rheumatoid arthritis and Crohn's disease.
Potential effects: Thalidomide-piperazine-Boc has potential effects similar to thalidomide, which include anti-inflammatory and immunomodulatory effects. However, Thalidomide-piperazine-Boc may have greater specificity and potency than thalidomide due to the addition of the piperazine-Boc moiety. It may also inhibit angiogenesis, which can prevent or slow tumor growth.
Product mechanism: The exact mechanism of action for Thalidomide-piperazine-Boc is not fully understood, but it is believed to work similarly to thalidomide. It is an immunomodulatory drug that can affect the activity of T-cells and other immune cells involved in inflammation and autoimmune diseases. It may also inhibit angiogenesis by affecting the expression of certain genes involved in blood vessel formation.
Safety: As Thalidomide-piperazine-Boc is still being researched, there is limited information on its safety profile. However, it is likely to have a similar safety profile to thalidomide, which can cause serious side effects such as nerve damage, birth defects, and blood clots. It should not be taken during pregnancy, and caution must be exercised when prescribing and using it.
Side effects: Common side effects of Thalidomide-piperazine-Boc may include fatigue, nausea, diarrhea, and constipation. More serious side effects, such as nerve damage, blood clots, and birth defects, are rare but can occur. Thalidomide-piperazine-Boc may also increase the risk of infections, so caution must be taken in individuals with compromised immune systems.
Dosing information: As Thalidomide-piperazine-Boc is still being researched, there is limited information on dosing. Preliminary studies suggest it may be effective at lower doses than thalidomide, but more studies are needed to determine optimal dosing. It should always be taken as directed by a healthcare professional.
Conclusion: Thalidomide-piperazine-Boc is a derivative of thalidomide that is being researched as a potential treatment for cancer and autoimmune diseases. Its mechanism of action is believed to be similar to thalidomide, with the potential for enhanced specificity and potency. While research into the health benefits of Thalidomide-piperazine-Boc is ongoing, it appears to have a similar safety profile to thalidomide, with the potential for serious side effects such as nerve damage and birth defects. If you are experiencing cancer or an autoimmune disease that may benefit from Thalidomide-piperazine-Boc, speak to your healthcare professional about whether it may be an appropriate treatment option for you
